Dashboard
Manage Tickers

ZVRAZEVRA THERAPEUTICS, INC.

Nasdaq kempharm.com


$ 5.16 $ -0.01 (-0.29 %)    

Wednesday, 08-May-2024 15:59:37 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 5.16
$ 4.80
$ 0.00 x 0
$ 0.00 x 0
$ 4.80 - $ 5.24
$ 3.89 - $ 7.28
229,376
na
178.05M
$ 3.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-01-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-07-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-30-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-13-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-12-2021 12-31-2020 10-K
14 10-30-2020 09-30-2020 10-Q
15 08-12-2020 06-30-2020 10-Q
16 05-13-2020 03-31-2020 10-Q
17 02-28-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-13-2019 06-30-2019 10-Q
20 05-14-2019 03-31-2019 10-Q
21 03-01-2019 12-31-2018 10-K
22 11-09-2018 09-30-2018 10-Q
23 08-10-2018 06-30-2018 10-Q
24 05-11-2018 03-31-2018 10-Q
25 03-30-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-10-2017 06-30-2017 10-Q
28 05-22-2017 03-31-2017 10-Q
29 03-10-2017 12-31-2016 10-K
30 11-10-2016 09-30-2016 10-Q
31 08-11-2016 06-30-2016 10-Q
32 05-13-2016 03-31-2016 10-Q
33 03-16-2016 12-31-2015 10-K
34 11-13-2015 09-30-2015 10-Q
35 08-14-2015 06-30-2015 10-Q
36 05-29-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

as-of-march-31-2024-zevra-therapeutics-cash-cash-equivalents-and-investments-were-527m-april-5-2024-the-company-announced-refinancing-of-existing-debt-with-up-to-100m-in-committed-capital-expected-to-provide-cash-runway-into-2026
As of March 31, 2024, Zevra Therapeutics' ...
05/08/2024 11:32:10

zevra-therapeutics-q1-2024-gaap-eps-040-beats-048-estimate-sales-3425m-miss-3764m-estimate
Zevra Therapeutics Q1 2024 GAAP EPS $(0.40...
05/08/2024 11:29:02

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(...

zevra-therapeutics-presents-new-data-on-long-term-safety-and-efficacy-of-arimoclomol-as-treatment-for-niemann-pick-disease-type-c-at-simd-45th-annual-meeting
Zevra Therapeutics Presents New Data On Lo...
04/15/2024 21:07:15

"These observed long-term clinical benefits add to the body of evidence for arimoclomol that supports its tolerability and ...

zevra-therapeutics-announced-that-it-has-entered-into-a-new-credit-facility-to-refinance-existing-debt-with-up-to-100m-in-committed-capital-under-new-credit-facility
Zevra Therapeutics Announced That It Has E...
04/10/2024 11:33:58

hc-wainwright--co-reiterates-buy-on-zevra-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Zevr...
04/03/2024 11:04:01

HC Wainwright & Co. analyst Oren Livnat reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and maintains $15 price t...

cantor-fitzgerald-reiterates-overweight-on-zevra-therapeutics
Cantor Fitzgerald Reiterates Overweight on...
04/01/2024 12:30:23

Cantor Fitzgerald analyst Louise Chen reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight.

zevra-therapeutics-q4-earnings-insights
Zevra Therapeutics: Q4 Earnings Insights
03/28/2024 21:05:07

zevra-therapeutics-q4-2023-gaap-eps-040-misses-027-estimate-sales-13217m-beat-11738m-estimate
Zevra Therapeutics Q4 2023 GAAP EPS $(0.40...
03/28/2024 21:05:05

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of ...

earnings-scheduled-for-march-28-2024
Earnings Scheduled For March 28, 2024
03/28/2024 09:24:44

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

earnings-outlook-for-zevra-therapeutics
Earnings Outlook For Zevra Therapeutics
03/27/2024 16:02:32

zevra-therapeutics-reports-data-from-phase-2-clinical-trial-of-kp1077-for-idiopathic-hypersomnia-says-kp1077-demonstrates-clinically-meaningful-benefits-for-key-ih-symptoms
Zevra Therapeutics Reports Data From Phase...
03/26/2024 20:32:26

The Company plans to request an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration to seek guidance on th...

william-blair-initiates-coverage-on-zevra-therapeutics-with-outperform-rating
William Blair Initiates Coverage On Zevra ...
03/12/2024 11:43:03

William Blair analyst Tim Lugo initiates coverage on Zevra Therapeutics (NASDAQ:ZVRA) with a Outperform rating.

hc-wainwright--co-reiterates-buy-on-zevra-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Zevr...
03/05/2024 11:40:59

HC Wainwright & Co. analyst Oren Livnat reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and maintains $15 price t...

zevra-therapeutics-says-fda-has-extended-review-period-for-new-drug-application-for-arimoclomol-as-treatment-for-niemann-pick-disease-type-c
Zevra Therapeutics Says FDA Has Extended R...
03/04/2024 12:33:38

In addition, the FDA has set a new Prescription Drug User Fee Act ("PDUFA") action date of September 21, 2024, and has ...

zevra-therapeutics-filed-for-resale-of-up-to-23m-shares-by-the-selling-stockholders
Zevra Therapeutics Filed For Resale Of Up ...
02/05/2024 11:42:33

-S-3

zevra-reports-fda-acceptance-of-resubmission-of-nda-for-arimoclomol-as-treatment-for-niemann-pick-disease-type-c
Zevra Reports FDA Acceptance Of Resubmissi...
01/08/2024 12:43:09

As a result, the FDA has assigned a PDUFA action date of June 21, 2024, and currently intends to present the resubmission for d...

microsoft-to-rally-over-20-here-are-10-top-analyst-forecasts-for-thursday
Microsoft To Rally Over 20%? Here Are 10 T...
12/28/2023 13:35:57

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

hc-wainwright--co-maintains-buy-on-zevra-therapeutics-raises-price-target-to-15
HC Wainwright & Co. Maintains Buy on Zevra...
12/28/2023 11:13:44

HC Wainwright & Co. analyst Oren Livnat maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price targe...

zevra-therapeutics-resubmits-its-new-drug-application-for-arimoclomol-for-niemann-pick-disease-type-c-to-fda-zevra-expects-the-application-to-be-classified-as-a-class-ii-submission-which-would-be-subject-to-a-review-period-by-fda-within-six-months
Zevra Therapeutics Resubmits Its New Drug ...
12/27/2023 12:33:53

zevra-therapeutics-q3-eps-040-misses-030-estimate-sales-290m-miss-338m-estimate
Zevra Therapeutics Q3 EPS $(0.40) Misses $...
11/07/2023 12:02:42

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION